IceCure Medical Ltd(ICCM)Earnings, Financials & Key Ratios
ICCM•NASDAQ
$5.96
Price updated Jun 27, 2026
AboutIceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Show more
- Revenue$3M+2.7%
- EBITDA-$15M+3.7%
- Net Income-$15M+1.7%
- EPS (Diluted)-7.10+21.1%
- Gross Margin36.28%-17.7%
- EBITDA Margin-437.97%+6.2%
- Operating Margin-446.7%+6.3%
- Net Margin-445.61%+4.3%
- ROE-188.78%-17.5%
ICCM Price & Volume
IceCure Medical Ltd (ICCM) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Challenge Capital Runway Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"IceCure Medical faces a precarious path to commercialization as its proprietary cryoablation technology struggles to achieve consistent revenue growth, with quarterly fluctuations ranging from a 48.1% contraction to a 102.4% expansion. The company's reliance on lumpy international distributor orders and a structural margin deficit, where gross margins remain below 52.4%, necessitates a shift toward a more predictable clinical adoption model. Investors should monitor the company's $8.1M cash position against a TTM net loss exceeding $15M, as the current burn rate suggests a high probability of future shareholder dilution to fund ongoing R&D and regulatory milestones."
Verdict Logic
the company's current liquidity buffer of $8.1M is insufficient to cover the persistent quarterly operating losses that frequently exceed $4M, creating an imminent risk of severe shareholder dilution.
ICCM Growth Metrics
IceCure Medical Ltd (ICCM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years16.05%
5 Years-3.72%
3 Years3.08%
TTM8.92%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM17.78%
Return on Capital
10 Years-115.11%
5 Years-109.29%
3 Years-142.83%
Last Year-187.2%
ICCM Recent Earnings
IceCure Medical Ltd (ICCM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.06-100.0%
$0.03
Rev
$911,000-32.2%
$1M
Q2 2026
Mar 17, 2026Metric
Actual
Est
EPS
$0.06-50.0%
$0.04
Rev
$1M+0.0%
$1M
Q4 2025
Nov 19, 2025Metric
Actual
Est
EPS
$0.06-20.0%
$0.05
Rev
$850,000-34.6%
$1M
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.06+0.0%
$0.06
Rev
$525,000-17.8%
$639,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.06vs $0.03-100.0% | $911,000vs $1M-32.2% |
| Q2 2026 | Mar 17, 2026 | $0.06vs $0.04-50.0% | $1Mvs $1M+0.0% |
| Q4 2025 | Nov 19, 2025 | $0.06vs $0.05-20.0% | $850,000vs $1M-34.6% |
| Q3 2025 | Aug 13, 2025 | $0.06vs $0.06+0.0% | $525,000vs $639,000-17.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for IceCure Medical Ltd (ICCM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.96 | $13.42M | -0.84 | 2.67% | -445.61% | -188.78% | — | |
| $15.43 | $1.76B | -12.65 | 8.28% | -25.66% | -50.82% | — | |
| $0.42 | $58.92M | 14.00 | 14.21% | 1.5% | 3.68% | — | |
| $9.30 | $1.41B | -9.69 | 24.95% | -21.07% | -443.09% | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — | |
| $404.27 | $143.58B | 51.37 | 20.51% | 28.15% | 16.89% | — |
Compare ICCM vs Peers
IceCure Medical Ltd (ICCM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ICCM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ICCM Frequently Asked Questions
IceCure Medical Ltd (ICCM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is IceCure Medical Ltd's revenue?
IceCure Medical Ltd (ICCM) reported $3.6M in revenue for fiscal year 2025. This represents a 234% increase from $1.1M in 2014.
How fast is IceCure Medical Ltd growing?
IceCure Medical Ltd (ICCM) grew revenue by 2.7% over the past year. Growth has been modest.
Is ICCM profitable?
IceCure Medical Ltd (ICCM) reported a net loss of $15.7M for fiscal year 2025.
Dividend & Returns
What is ICCM's return on equity?
IceCure Medical Ltd (ICCM) has a return on equity (ROE) of -188.8%. Negative ROE indicates the company is unprofitable.
What is IceCure Medical Ltd's free cash flow?
IceCure Medical Ltd (ICCM) had negative free cash flow of $15.3M in fiscal year 2025, likely due to heavy capital investments.